Search Results

Interrogating T-cell apoptotic priming to improve CAR-T persistence in treatment of lymphoid malignancies

cells are made from a patient’s own immune cells, altered so that they specifically recognize and kill the patient’s cancer cells. They are effective …

Anthony Letai

Dr. Letai is a Professor of Medicine at Harvard Medical School and Cancer Institute. He began his studies in apoptosis and hematologic malignancies a…

Defining mechanisms of sensitivity and resistance to PI3K gamma inhibition in AML

The goal of our laboratory is to discover, study, and the translate new leukemia therapies to the clinic. In this project, we are studying a signaling…

Steven Park

I am a physician scientist, specializing in lymphoma therapy. My area of research is focused on the development of new therapeutic approaches in lymph…

Our commitment to DEI and Health Equity

About Us

Supplier resources

Get all the tools you need to work better with Blood Cancer United.

Developing Novel Immunotherapies for Challenging Lymphomas

This team science program from Washington University will develop new immunotherapy treatments for patients with hard to treat or incurable lymphomas.…

Financial assistance

Financial assistance programs from Blood Cancer United are making costly blood cancer care more accessible to patients.

Financial Support

Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast

Black and Hispanic individuals diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. Using an innovative data source, this s…

H. Irene Su, MD

Dr. Su is Professor of Obstetrics, Gynecology and Reproductive Science in the Division of Reproductive Endocrinology and Infertility at the University…

Impact of State Health Insurance Mandates on Affordability and Utilization of Fertility Preservation in Adolescent and Young Adults with Blood Cancers

Fertility preservation (FP) treatments can prevent infertility caused by blood cancer. However, FP costs are high, and these services are typically no…

Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO Study

In collaboration with oncology practice sites, this study will implement a intervention trial to test the effectiveness of two community oncology s…

Carma Bylund

Zachary Epstein-Peterson

I am a researcher focusing on new treatments for lymphomas with a particular focus on /cutaneous lymphomas. Since entering the field of hematology/on…

Martin Dreyling

Martin Dreyling is Professor of Medicine and head of the lymphoma programme at the Department of Medicine III, LMU Hospital Munich. He studied at the …

Identifying the oncogenic cooperation between IRF4 and MYD88l265p and their impact on the Tumor Microenvironment of Waldenstrom Macroglobulinemia

Although many patients with IgM MGUS remain asymptomatic, some of them progress to Waldenstrom Macroglobulinemia (WM) requiring treatment. Recently, w…

Shazia Nakhoda

Dr. Nakhoda is a in the department of hematology/oncology at Fox Chase Cancer Center. She serves as steering committee member for the Leukemia & Lymp…

RECONNECT: Overcoming Racial and Ethnic Inequity in Clinical Trial Enrollment via Clinical Trial Nurse Navigation and Provider Communication Training

This study will implement a didactic course for providers to improve the quality of communication around structural racism, mistrust, implicit biases…

Addressing Inequities in Access to Care for Patients with Hematologic Malignancy: Understanding the Impact of Telehealth Policies in Medicaid

Telehealth could improve access for Medicaid patients with a blood cancer who experience barriers to specialty care, but not all specialists offer it.…